Table Graph
   

janus kinase (JAK) inhibitor - versus potential COVID-19 treatments - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.52 [0.30, 0.89]< 10%3 studies (3/-)99.1 %lownot evaluable highcrucial-
death or transfer to ICU 0.93 [0.87, 0.99]< 10%1 study (-/1)98.6 %NAnot evaluable crucial-
deaths 0.48 [0.34, 0.68]< 10%6 studies (5/1)100.0 %NAserious crucial-
clinical deterioration 0.11 [0.01, 2.21]< 10%1 study (1/-)92.3 %NAnot evaluable important-
clinical improvement 2.07 [1.21, 3.53]> 10%4 studies (4/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.98 [1.05, 3.71]> 10%2 studies (2/-)98.3 %lownot evaluable highimportant-
clinical improvement (21-day) 1.50 [0.22, 10.08]> 10%1 study (1/-)66.1 %NAnot evaluable important-
clinical improvement (28-day) 1.92 [0.96, 3.82]> 10%3 studies (3/-)96.8 %lownot evaluable highimportant-
clinical improvement (7-day) 2.38 [0.38, 14.70]> 10%1 study (1/-)82.3 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.67 [0.84, 3.33]> 10%1 study (1/-)92.7 %NAnot evaluable important-
mechanical ventilation 0.08 [0.01, 0.86]< 10%2 studies (2/-)98.1 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 5.54 [1.01, 30.50]> 10%1 study (1/-)97.5 %NAnot evaluable important-
ICU admission 0.19 [0.10, 0.39]< 10%1 study (-/1)100.0 %NAnot evaluable non important-
recovery 1.57 [0.77, 3.20]> 10%1 study (1/-)89.3 %NAnot evaluable non important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 0.11 [0.01, 2.21]< 10%1 study (1/-)92.3 %NAnot evaluable important-
acute kidney injury 0.43 [0.14, 1.34]< 10%1 study (-/1)92.7 %NAnot evaluable non important-
adverse events 0.43 [0.04, 4.22]< 153%3 studies (3/-)76.4 %some concernnot evaluable moderatenon important-
arrhythmia 0.16 [0.03, 0.90]< 10%1 study (-/1)98.1 %NAnot evaluable non important-
elevated liver enzymes 0.52 [0.18, 1.51]< 10%1 study (-/1)88.5 %NAnot evaluable non important-
Myocardial infarction 0.87 [0.19, 3.92]< 10%1 study (-/1)57.2 %NAnot evaluable non important-
venous thromboembolism 5.23 [0.42, 65.62]< 10%1 study (-/1)10.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons